DLL3xCD3 bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing.
Bispecific T-cell–engaging antibody that binds DLL3 on tumor cells and CD3 on T cells, forming an immune synapse to activate and redirect cytotoxic T cells to kill DLL3-expressing cancer cells.
YES
DIRECT
DLL3xCD3 T-cell–engaging antibody bridges DLL3 on target cells to CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and kill DLL3-expressing cells.
DLL3xCD3 bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells to redirect and activate cytotoxic T-cell killing.
Bispecific T-cell–engaging antibody that binds DLL3 on tumor cells and CD3 on T cells, forming an immune synapse to activate and redirect cytotoxic T cells to kill DLL3-expressing cancer cells.
NO
INDIRECT
Binds CD3ε on T cells to activate and redirect them toward DLL3+ tumor cells; the T cells then kill DLL3-expressing cancer cells via perforin/granzyme release. CD3+ T cells are not the cytotoxic target.
Investigational CEACAM5-directed antibody-drug conjugate (also known as SGN-CEACAM5C; SAR445953) with a camptothecin-class topoisomerase I inhibitor payload; binds CEACAM5 on tumor cells, is internalized, and releases payload to induce DNA damage and cell death.
CEACAM5-targeted monoclonal antibody linked to a camptothecin-class topoisomerase I inhibitor; upon binding CEACAM5 on tumor cells, the ADC is internalized and releases the cytotoxic payload to cause TOP1-mediated DNA damage and tumor cell death.
YES
DIRECT
ADC binds CEACAM5 on tumor cells, is internalized, and releases a camptothecin-class TOP1 inhibitor that causes DNA damage leading to tumor cell death.
Investigational CEACAM5-directed antibody-drug conjugate (also known as SGN-CEACAM5C; SAR445953) with a camptothecin-class topoisomerase I inhibitor payload; binds CEACAM5 on tumor cells, is internalized, and releases payload to induce DNA damage and cell death.
CEACAM5-targeted monoclonal antibody linked to a camptothecin-class topoisomerase I inhibitor; upon binding CEACAM5 on tumor cells, the ADC is internalized and releases the cytotoxic payload to cause TOP1-mediated DNA damage and tumor cell death.
NO
INDIRECT
The ADC binds CEACAM5 on tumor cells, is internalized, and releases a camptothecin-class TOP1 inhibitor that induces DNA damage and cell death; topoisomerase I is the intracellular payload target, so its expression alone does not make cells a direct target.
A minimally blocking anti-CTLA-4 monoclonal antibody (immune checkpoint–targeting biologic) administered intravenously every 3 weeks, designed to bind CTLA-4 while minimally blocking CD80/CD86 interaction to enhance anti-tumor immunity with potentially reduced toxicity.
Human IgG1 monoclonal antibody targeting CTLA-4 that minimally blocks CTLA-4 binding to CD80/CD86 while engaging Fc receptors to deplete intratumoral regulatory T cells and reduce their proliferation, thereby relieving immune suppression and enhancing effector T-cell–mediated antitumor responses with potentially lower toxicity.
YES
DIRECT
IgG1 anti-CTLA-4 binds CTLA-4 on Tregs and engages Fc gamma receptors on NK cells/macrophages to mediate ADCC/ADCP (and possibly complement), depleting CTLA-4–expressing cells.